Errahmani Mohamed Yassir, Locquet Médéa, Spoor Daan, Jimenez Gaelle, Camilleri Jérémy, Bernier Marie-Odile, Broggio David, Monceau Virginie, Ferrières Jean, Thariat Juliette, Boveda Serge, Kirova Youlia, Loap Pierre, Langendijk Johannes A, Crijns Anne, Jacob Sophie
Laboratory of Epidemiology, Institute for Radiation Protection and Nuclear Safety (IRSN), Fontenay-Aux-Roses, France.
University Paris-Saclay, Gif-sur-Yvette, France.
Front Oncol. 2022 Jul 4;12:892882. doi: 10.3389/fonc.2022.892882. eCollection 2022.
Previous studies suggested that radiation therapy (RT) for breast cancer (BC) can induce cardiac arrhythmias and conduction disorders. However, the association with mean heart dose and specific cardiac substructures doses was less studied.
We conducted a nested case-control study based on French BC patients, enrolled in the European MEDIRAD-BRACE study (https://clinicaltrials.gov, Identifier: NCT03211442), who underwent three-dimensional conformal radiation therapy (3D-CRT) between 2009 and 2013 and were retrospectively followed until 2019. Cases were incident cases of cardiac arrhythmia. Controls without arrhythmia were selected with propensity-scored matching by age, duration of follow-up, chemotherapy, hypertension, and diabetes (ratio 1:4 or 5). Doses to the whole heart (WH), left and right atria (LA and RA), and left and right ventricles (LV and RV) were obtained after delineation with multi-atlas-based automatic segmentation.
The study included 116 patients (21 cases and 95 controls). Mean age at RT was 64 ± 10 years, mean follow-up was 7.0 ± 1.3 years, and mean interval from RT to arrhythmia was 4.3 ± 2.1 years. None of the results on association between arrhythmia and cardiac doses reached statistical significance. However, the proportion of right-sided BC was higher among patients with arrhythmia than among controls (57% vs. 51%, OR = 1.18, = 0.73). Neither mean WH dose, nor LV, RV, and LA doses were associated with an increased risk of arrhythmia (OR = 1.00, > 0.90). In contrast, the RA dose was slightly higher for cases compared to controls [interquartile range (0.61-1.46 Gy) vs. (0.49-1.31 Gy), = 0.44], and a non-significant trend toward a potentially higher risk of arrhythmia with increasing RA dose was observed (OR = 1.19, = 0.60). Subanalysis according to BC laterality showed that the association with RA dose was reinforced specifically for left-sided BC (OR = 1.76, = 0.75), while for right-sided BC, the ratio of mean RA/WH doses may better predict arrhythmia (OR = 2.39, = 0.35).
Despite non-significant results, our exploratory investigation on BC patients treated with RT is the first study to suggest that right-sided BC patients and the right atrium irradiation may require special attention regarding the risk of cardiac arrhythmia and conduction disorders. Further studies are needed to expand on this topic.
先前的研究表明,乳腺癌(BC)的放射治疗(RT)可诱发心律失常和传导障碍。然而,关于平均心脏剂量和特定心脏亚结构剂量之间的关联研究较少。
我们基于法国BC患者开展了一项巢式病例对照研究,这些患者纳入了欧洲MEDIRAD-BRACE研究(https://clinicaltrials.gov,标识符:NCT03211442),于2009年至2013年间接受三维适形放射治疗(3D-CRT),并进行回顾性随访至2019年。病例为心律失常的新发病例。通过年龄、随访时间、化疗、高血压和糖尿病进行倾向评分匹配,选择无心律失常的对照(比例为1:4或5)。在使用基于多图谱的自动分割进行轮廓勾画后,获取全心(WH)、左心房和右心房(LA和RA)以及左心室和右心室(LV和RV)的剂量。
该研究纳入了116例患者(21例病例和95例对照)。RT时的平均年龄为64±10岁,平均随访时间为7.0±1.3年,从RT到心律失常的平均间隔时间为4.3±2.1年。心律失常与心脏剂量之间的关联结果均未达到统计学显著性。然而,心律失常患者中右侧BC的比例高于对照组(57%对51%,OR = 1.18, = 0.73)。平均WH剂量、LV、RV和LA剂量均与心律失常风险增加无关(OR = 1.00, > 0.90)。相比之下,病例组的RA剂量略高于对照组[四分位数间距(0.61 - 1.46 Gy)对(0.49 - 1.31 Gy), = 0.44],并且观察到随着RA剂量增加,心律失常风险有潜在升高的非显著性趋势(OR = 1.19, = 0.60)。根据BC侧别进行的亚分析表明,对于左侧BC,与RA剂量的关联尤为明显(OR = 1.76, = 0.75),而对于右侧BC,平均RA/WH剂量的比值可能更能预测心律失常(OR = 2.39, = 0.35)。
尽管结果无统计学显著性,但我们对接受RT治疗的BC患者的探索性研究首次表明,右侧BC患者和右心房照射在心律失常和传导障碍风险方面可能需要特别关注。需要进一步的研究来拓展这一主题。